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Abstract 
 
Background: Dementia is increasingly recognised as life-limiting condition. Although 
the benefits of acetylcholinesterase inhibitors (AChEIs) on cognition and function are 
well established, their effect on survival is less clear.  
 
Objective: To investigate associations between AChEI prescription and mortality in 
patients with Alzheimer’s dementia in a naturalistic setting, using detailed baseline 
data on cognition, functioning, and mental and physical wellbeing. 
 
Methods: We used a large mental health care database in South London, linked to 
Hospital Episode Statistics and Office for National Statistics mortality data, to 
assemble a retrospective cohort. We conducted a survival analysis adjusting for a 
wide range of potential confounders using propensity scores to reduce the impact of 
confounding by indication. 
 
Results: Of 2464 patients with Alzheimer’s disease, 1261 were prescribed AChEIs. 
We detected a strong association between AChEI receipt and lower mortality (hazard 
ratio=0.57; 95% CI 0.51-0.64). This remained significant after controlling for a broad 
range of potential confounders including psychotropic co-prescription, symptom 
severity, functional status and hospital admissions (hazard ratio=0.77; 95% CI 0.67-
0.87). 
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Conclusions: In a large cohort of patients with Alzheimer’s disease, AChEI 
prescription was associated with reduced risk of death by more than 20% in adjusted 
models. This has implications for individual care planning and service development.  
 
Keywords: Alzheimer’s disease; Acetylcholinesterase inhibitors (AChEIs); Treatment 
effect; Survival; Predictors 
 
Key points:  
• Acetylcholinesterase inhibitor prescription is less likely in patients of higher 
age, lower MMSE, who are unmarried and from more deprived areas. 
• Receipt of an acetylcholinesterase inhibitor was associated with reduced 
mortality in the whole sample by at least 20%. 
• Findings were robust to adjustment for a large number of confounders and 
propensity scores. 
• Greater survival benefits were detected in patients without hospital 
admission in the year prior to Alzheimer’s disease diagnosis.  
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Introduction 
 
Dementia is more frequently recorded on death certificates [1] and is now the leading 
reported cause of death for women in England and Wales [2]. Mean survival time with 
dementia varies between three to ten years [3], depending on study design but also 
potentially on dementia management.  Acetylcholinesterase inhibitors (AChEIs) are 
established in dementia treatment, and continuous treatment into the moderate-to-
severe stages of Alzheimer’s disease (AD) is associated with cognitive and functional 
benefits, as well as independence and home living [4, 5]. However, concerns have 
been raised about the cardiac safety of these agents, as well as risks of falls and 
hospital visits due to syncope, bradycardia, pacemaker insertion and hip fracture [6, 
7]. The extent to which these potential benefits and risks affect mortality remains 
unclear, as associations have been conflicting. While early evidence from randomised 
controlled trials [8], matched observational data [9], and a large cohort study [10], did 
not identify any association between AChEI use and mortality, more recent larger 
cohort studies [11,12] have reported improved survival, although study designs, 
cohorts and effect sizes have varied.  
 
Our aim was therefore to investigate the association of AChEI receipt with mortality in 
a large, naturalistic sample of patients with clinically diagnosed AD, taking into account 
baseline functioning, mental and physical wellbeing, as well as using propensity 
scores to minimise potential confounding by indication.  
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Methods 
 
Data source 
 
Data for this study were obtained from the South London and Maudsley NHS 
Foundation Trust (SLaM) Clinical Record Interactive Search (CRIS) application. SLaM 
is one of Europe’s largest healthcare providers for mental disorders and dementia, 
serving a geographic catchment of four South London boroughs (Lambeth, Lewisham, 
Southwark, and Croydon) with a population of over 1.2 million residents. SLaM 
provides specialist dementia assessment and care for all residents in the catchment 
areas, including those living in residential care and admitted to general hospitals. In 
2007-8 the CRIS application was developed to provide research access to 
anonymised copies of SLaM’s electronic health records within a robust governance 
framework [13, 14] including ethical approval as a data resource (Oxford Research 
Ethics Committee C, reference 08/H0606/71+5). CRIS has been linked to national 
data on hospitalisations (Hospital Episode Statistics; HES) and mortality which have 
permitted the analyses presented here. 
 
Sample 
 
CRIS was used to extract cases aged 65 years or older who received a first diagnosis 
of AD from SLaM services within the 4-year period between 1st Jan 2008 and 31st 
December 2012. Diagnoses are routinely coded using International Classification of 
Diseases, Tenth Revision (ICD-10) categories [15] and these stuctured data were 
supplemented by a bespoke natural language processing algorithm using General 
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Architecture for Text Engineering (GATE) software [16] which extracts diagnoses 
recorded in text fields [13, 16]. To minimise confounding morbidity, cases were 
excluded if the initial AD diagnosis was received from SLaM services providing liaison 
input to acute hospital inpatients, as were cases who died within 6 months of the first 
AD diagnosis.  
 
Measurements 
 
Demographic data were extracted from routinely completed fields and included age at 
AD diagnosis, gender, ethnicity (categorised into White-European and non-White) and 
marital status. Socioeconomic status was estimated from a neighbourhood-level index 
of multiple deprivation [17]. GATE-hosted applications were used to identify the 
following parameters from text fields [13], supplemented by information from 
structured fields when available: i) recorded prescription of AChEIs within 6 months of 
AD diagnosis (the primary exposure); ii) Mini-Mental State Examination (MMSE) [18] 
score closest to AD diagnosis; iii) recorded prescription of antipsychotic, 
antidepressant or hypnotic medication prior to AD diagnosis [13]. Data were also 
extracted from structured Health of the Nation Outcome Scales (HoNOS65+), routine 
measures of wellbeing used in UK mental health and dementia services [19]. 
Subscales on symptom severity and functional status were included in this analysis, 
using scores recorded closest to the AD diagnosis date. HoNOS65+ subscales are 
each rated 0 (no problem) to 4 (severe or very severe problem) which we dichotomised 
to ‘minor or no problem’ (0-1) and ‘mild to severe problems’ (2-4). From 
hospitalisations for physical disorders in the year prior to dementia diagnosis, the 
primary and first two secondary discharge diagnoses were extracted as indicators of 
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comorbidity. Mortality up to 22nd September 2015 was ascertained from linked national 
data and analysed as the primary outcome. Follow-up started 6 months after the AD 
diagnosis and ended either at death or the aforementioned censoring point.  
 
Statistical analysis 
 
STATA 13 software was used (Stata Corp LP, College Station, TX, USA). Patients 
prescribed AChEIs were compared to the remainder with respect to other covariates. 
Kaplan-Meier curves with log-rank tests were initially used to compare survival 
between exposure groups.  Cox regression models were used to investigate 
associations between AChEI prescription and all-cause mortality. In order to separate 
the measurement of exposures/covariates and the ascertainment of outcome, the 
sample was restricted to survivors at 6 months after dementia diagnosis, and the 
exposure comprised AChEI receipt up to that point. To reduce confounding by 
indication we calculated and adjusted for a propensity score [20] representing the 
probability of being treated with an AChEI based on a regression model which included 
all the aforementioned covariates. The propensity score was included in a Cox model 
in place of these covariates, followed by an analysis restricting the sample to patients 
at risk of receiving AChEI based on their propensity score. We further established a 
case-control cohort by matching AChEI receivers and non-receivers on their exact 
MMSE score at dementia diagnosis.  
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Results 
 
Population characteristics  
 
We identified 3199 patients diagnosed with AD in the observation period. Patients who 
died within 6 months of diagnosis, patients under the age of 65, patients active to 
liaison psychiatry services at the time of AD diagnosis, and patients who received 
AChEIs but not within 6 months of AD diagnosis were excluded. This resulted in 2464 
included patients with AD of whom 1220 (49.5%) died within the follow-up period. The 
mean (SD) follow-up time was 3.66 (1.69) years.   
 
Of the 2464 cases at baseline, 1261 (51.2%) were prescribed AChEIs and 
characteristics of AChEI users and non-users are compared in Table 1. Of the 21 
patient characteristics associated with not being prescribed AChEIs, 13 were also 
associated with higher mortality in age- and gender-adjusted models (Table 2). 
Factors associated with increased mortality in these models were: increased age, 
psychotropic medication use prior to AD diagnosis (antipsychotic or 
hypnotic/anxiolytic), agitated behaviour, hallucinations or delusions, physical illness or 
disability, activities of daily living impairment, impaired occupational/recreational 
activities, and all hospitalisation diagnoses apart from musculoskeletal and digestive 
system disorders. Factors associated with lower mortality were: female gender, non-
White ethnicity and higher MMSE score. When all aforementioned covariates and 
AChEI prescription were entered into the same model, the following factors remained 
independently significant (p<0.05) covariates: age, gender, ethnicity, MMSE score, 
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physical illness or disability, impaired activities of daily living, and hospitalisations with 
cancer or genitourinary disease diagnoses.  
 
After matching for exact MMSE scores, 953 patients remained in each group. Mean 
(SD) MMSE score was 19.8 (5.8), mean (SD) follow-up time 3.0 (1.7) years. Cohorts 
did not differ significantly in numbers of deaths and demographics (age, gender, 
ethnicity, marital status, deprivation score). 
 
AChEIs and survival 
 
Kaplan-Meier curves (Supplementary Figure 1) comparing survival between AChEI 
users and non-users indicated substantially lower mortality in those receiving this 
treatment (log-rank test; p<0.01). Further Cox regression models (Table 3) confirmed 
strong associations between AChEI prescription and reduced all-cause mortality 
which remained significant after adjusting for all covariates. The most substantial 
changes in the strength of association occurred following adjustment for age and 
gender, and then again following further adjustment for other demographic factors and 
cognitive function at baseline. Standard propensity scores were created using all 
variables from the fully adjusted model. For this analysis, 2143 patients lay within the 
region of common support (i.e. where there was substantial overlap between 
characteristics of treated and untreated groups) with propensity scores ranging 
between 0.101 to 0.895; of these, 1181 (55.1%) were prescribed AChEIs. In summary, 
hazard ratios remained virtually unchanged compared to the fully adjusted model. In 
the MMSE-matched sample, hazard ratio for death was 0.79 (95% CI 0.69-0.89) and 
thereby very similar to the fully adjusted model from the original cohort.  
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In further analysis we stratified the sample into two groups by the median MMSE, 
score but found no substantial difference in associations of interest in patients with 
milder cognitive impairment at diagnosis (MMSE 21; age- and gender-adjusted 
HR=0.75; 95% CI 0.62-0.92) compared to those with worse cognitive scores 
(MMSE<21; age- and gender-adjusted HR=0.70; 95% CI 0.59-0.82). However, the 
association between AChEI prescription and lower mortality was more pronounced in 
patients who did not have a hospital admission in the year prior to AD diagnosis 
(HR=0.62; 95% CI 0.53-0.71) compared to those who did (HR=0.74; 95% CI 0.62-
0.89; adjusted for age and gender). 
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Discussion 
 
In our analysis of a large sample receiving routine assessment and care for AD, 
mortality was more than 40% reduced in those prescribed AChEIs. This association 
was attenuated to around 20%, but remained significant, after controlling for a broad 
range of confounders, including psychotropic prescription, mental health symptoms, 
general physical health, functional status and hospitalisations with physical illness in 
the year prior to dementia diagnosis. The group of patients not receiving AChEIs did 
have an adverse health and functional profile, with 13 of the 21 patient characteristics 
associated with non-prescription also significantly associated with higher mortality. 
However, our findings remained robust to cognitive score matching, propensity score 
adjustment, and sensitivity analyses to address potential bias by indication.  
 
Our findings are consistent with some large scale cohort studies, which have reported 
lower mortality associated with AChEI use. Nordstrom and colleagues [11] followed 
7073 patients on the Swedish Dementia Registry, of whom 5159 were prescribed 
AChEIs. After adjusting for demographic factors, residency, presence of a care 
package, cognitive and nutritional state, co-morbid cerebrovascular and 
cardiovascular disease, as well as certain medications (antihypertensives, 
antidiabetics, antidepressants, and neuroleptics) substantial reductions in myocardial 
infarctions (hazard ratio=0.62) and mortality (hazard ratio=0.64) were detected, which 
remained significant after matching for propensity scores. Similarly, a more recent 
study using Taiwan’s National Health Insurance Research Database found that people 
with neurodegenerative dementia treated with any anti-dementia drug had comparable 
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survival to a group without dementia after adjusting for demographic factors, urbanicity 
and a physical health co-morbidity index [12]. However, the above studies were not 
able to fully account for psychotropic prescription, dementia subtype diagnosis, mental 
health symptoms, cognitive function at presentation, or a wider range of co-
morbidities. 
 
Although almost 50% of patients died within the follow-up period, survival time until 
death or censoring was within range of what is reported in the literature [3]. Our 
findings regarding other factors influencing mortality in dementia cohorts are in line 
with those from previous studies, including older age, male gender, worse cognitive 
impairment and worse functional abilities [10, 11, 21]. These remained significant in a 
fully adjusted model supporting the comparability of our findings. White ethnicity was 
independently associated with a higher mortality risk, which might possibly be viewed 
as unexpected, given levels of disadvantage experienced by minority ethnic groups; 
however, this observation is in line with previous research in this database and the 
United States  [22, 23].  
 
Although they cannot be inferred directly from our data, a number of factors are likely 
to underlie the observed prolonged survival. While these include the direct effect of 
AChEIs on cognition and functioning which might have a positive impact on survival 
[24, 25], AChEI use might possibly be a proxy marker for increased family involvement 
and requests for more assertive intervention in AD [24]. Indeed, in our sample people 
receiving AChEIs were more likely to be married and to be residing in wealthier 
neighbourhoods, and were less likely to have difficulties with living conditions or social 
relationships compared to AChEI non-users. However, the survival benefit associated 
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with AChEI prescription remained strong and statistically significant after adjustment 
for these factors. Of potential relevance, there is growing recognition of acetylcholine’s 
widespread presence in the body [26] and its hypothetically beneficial role in the 
cardiovascular system, where vagotonic stimulation improves survival in heart failure 
in animal models [27]. Other studies have suggested that AChEIs have anti-
inflammatory properties [28] and reduce markers of endothelial and platelet activation 
[29]. Hence Nordstrom and colleagues [11] speculated that AChEIs could influence 
plaque stability in atherosclerosis or improve cardiac function by reducing oxygen 
demands. This is further supported by the observation that higher doses of AChEIs 
appear to lead to better survival in patients with Alzheimer’s disease [11], although we 
did not have sufficient data to test dose-response associations in our sample. 
 
This study has a number of strengths. A large sample was analysed, drawn from a 
near-monopoly dementia assessment and care provider for an ethnically and socially 
diverse population, maximising the representativeness of the sample to its source 
population. We had sufficient statistical power to control for a range of potential 
confounding factors, which to our knowledge superseded those captured in any 
previous study of this scale. Our findings were additionally robust to a series of 
sensitivity analyses, including propensity score adjustments.  
 
Limitations, however, include the fact that this was an observational study and 
therefore inevitably subject to residual confounding. Noticeable differences in baseline 
factors existed between AChEI user and non-users and it is likely that healthier 
patients were prescribed AChEIs more frequently. Although we used propensity 
scores to perform sensitivity analyses, confounding by indication can never be entirely 
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ruled out in an observational study. There might be further confounders we are not 
able to measure. Most notably, we did not have sufficient information to adjust for level 
of education, although it is worth bearing in mind that the index of neighbourhood-level 
socio-economic status was associated with likelihood of receiving AChEIs, but not with 
mortality. In addition, a number of prospective studies have not found any association 
between educational level and survival in AD [10, 21]. Symptom severity and 
functional status were ascertained through the HoNOS65+ scale, which is a widely 
used routine measure of clinical outcome in mental health and dementia services in 
the UK. It is important to recognise that its subscales are relatively brief measures and 
do not provide the level of detail that might be required for specific outcomes. Physical 
co-morbidity was primarily measured through linked data on hospitalisations which will 
only have captured severe disorders requiring inpatient care. Nevertheless, the British 
Hospital Episode Statistics database has been previously used to identify patient 
cohorts with certain characteristics with a high degree of accuracy and outcome 
prediction [30].  
 
Conclusions 
 
Our results suggest that people with AD who are prescribed AChEIs have reduced 
mortality by approximately 40%, half of which remained independent of a range of 
potential confounding factors. As this is a retrospective observational study, stronger 
evidence could be achieved through replicating these results in a randomized 
controlled trial or a prospective cohort study. However, as AChEIs are now 
established in clinical practice and generally well-tolerated, depriving patients of 
AChEI prescription would be considered unethical. Our findings have potential 
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relevance for patients and their families, as well as for clinicians and policymakers in 
evaluating post-diagnostic care, although generalisability and underlying processes 
require further evaluation.   
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Tables 
 
Table 1: Sample characteristics by AChEI status 
 
Risk factors AChEI non-
receipt 
(n=1203) 
AChEI receipt 
(n=1261) 
P value* 
Socio-demographic status and cognitive function†  
Mean age at dementia diagnosis (SD) 83.1 (7.0) 80.8 (6.6) <0.01 
Female gender (%) 66.2% 67.1% 0.63 
Non-White ethnicity (%) 17.0% 19.4% 0.14 
Married or cohabiting status (%) 30.6% 42.9% <0.01 
Mean index of deprivation (SD) 26.7 (13.0) 25.5 (12.6) 0.02 
Mean MMSE score at diagnosis (SD) 17.8 (6.6) 20.1 (5.6) <0.01 
Psychotropic use prior to AD diagnosis (%) 
Antipsychotic  6.6% 5.1% 0.11 
Antidepressant  13.7% 13.4% 0.82 
Hypnotic/anxiolytic  6.2% 4.4% <0.05 
HoNOS65+ problem due to mental or physical symptoms (% with subscale scores 2-4)† 
Agitated behaviour 17.0% 10.9% <0.01 
Non-accidental self-injury 1.7% 0.5% 0.01 
Problem-drinking or drug taking 2.8% 1.9% 0.13 
Hallucinations or delusions 12.8% 8.2% <0.01 
Depressed mood 14.1% 10.7% 0.01 
Physical illness or disability 49.0% 32.3% <0.01 
HoNOS65+ functional problem (% with subscale scores 2-4)†  
Activities of daily living (ADLs) 58.8% 42.6% <0.01 
Living conditions 11.6% 5.8% <0.01 
Occupational/recreational activities 31.8% 21.9% <0.01 
Social relationships 15.0% 10.9% <0.01 
Recent hospitalisation diagnosis (ICD-10 code) (%) – in the year prior to AD diagnosis  
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Cancer (C00-C97) 2.5% 2.2% 0.66 
Musculoskeletal illness (M00-M99) 8.4% 5.1% <0.01 
Metabolic illness (E00-E90) 11.4% 6.7% <0.01 
Respiratory illness (J00-J99) 9.4% 4.2% <0.01 
Digestive system disorder (K00-K93) 11.1% 7.9% <0.01 
Injury or poisoning (S00-T98) 12.1% 6.5% <0.01 
Genitourinary disease (N00-N99) 13.6% 7.1% <0.01 
Circulatory disease (I00-I99) 23.9% 15.4% <0.01 
Neurologic disease (G00-G99) 3.8% 4.3% 0.56 
 
* independent samples t-test or chi2 test 
† at the time of AD diagnosis 
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Table 2: Unadjusted and adjusted analyses of associations between covariates and 
mortality after Alzheimer’s disease diagnosis 
 
Covariate status at/around diagnosis Association with mortality – Hazard ratio (95% CI) 
 Unadjusted Age and gender adjusted 
Age (per year increment)           1.08 (1.07-1.09)*              1.08 (1.07-1.09)* 
Female gender          0.77 (0.68-0.86)*              0.67 (0.60-0.75)* 
Non-white ethnicity          0.61 (0.51-0.72)*              0.73 (0.62-0.87)* 
Married or cohabiting status          1.12 (0.99-1.26)              1.03 (0.91-1.18) 
Deprivation score (per SD increase)          1.02 (0.97-1.08)              1.04 (0.98-1.10) 
MMSE score (per unit increment)          0.96 (0.95-0.97)*              0.96 (0.95-0.97)* 
Psychotropic use prior to AD diagnosis 
Antipsychotic          1.09 (0.87-1.37)              1.29 (1.03-1.63)* 
Antidepressant          1.05 (0.89-1.23)              1.16 (0.99-1.37) 
Hypnotic/anxiolytic          1.25 (0.99-1.58)              1.28 (1.02-1.62)* 
HoNOS65+ problem due to mental or physical symptoms  
Agitated behaviour          1.29 (1.10-1.51)*              1.32 (1.13-1.54)* 
Non-accidental self-injury          1.20 (0.72-1.99)              0.89 (0.53-1.49) 
Problem-drinking or drug taking          1.03 (0.70-1.52)              1.26 (0.85-1.87) 
Hallucinations or delusions          1.22 (1.02-1.46)*              1.30 (1.09-1.55)* 
Depressed mood          0.98 (0.82-1.17)              1.06 (0.89-1.27) 
Physical illness or disability          1.74 (1.55-1.95)*              1.52 (1.36-1.71)* 
HoNOS65+ functional problem 
Activities of daily living (ADLs)          1.66 (1.48-1.86)*              1.55 (1.38-1.74)* 
Living conditions          1.25 (1.03-1.52)*              1.20 (0.99-1.45) 
Occupational/recreational  activities          1.33 (1.17-1.51)*              1.34 (1.18-1.51)* 
Social relationships          0.96 (0.81-1.14)              1.08 (0.92-1.29) 
Recent hospitalisation diagnosis (ICD-10 code) – in the year prior to AD diagnosis 
Cancer (C00-C99)          1.84 (1.33-2.55)*              1.65 (1.19-2.29)* 
Musculoskeletal illness (M00-M99)          1.09 (0.88-1.37)              1.01 (0.80-1.26) 
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Metabolic illness (E00-E99)          1.38 (1.15-1.66)*              1.30 (1.08-1.56)* 
Respiratory illness (J00-J99)          1.54 (1.26-1.89)*              1.42 (1.15-1.74)* 
Digestive system disorder (K00-K99)          1.15 (0.96-1.39)              1.09 (0.91-1.31) 
Injury or poisoning (S00-T99)          1.53 (1.28-1.82)*              1.25 (1.05-1.49)* 
Genitourinary disease (N00-N99)          1.75 (1.48-2.06)*              1.46 (1.24-1.73)* 
Circulatory disease (I00-I99)          1.43 (1.26-1.65)*              1.23 (1.08-1.41)* 
Neurologic disease (G00-G99)          1.54 (1.19-1.97)*              1.67 (1.29-2.15)* 
 
* p<0.05 
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Table 3: Multivariate Cox regression analyses of association between receiving 
AChEI treatment and all-cause mortality in individuals with Alzheimer’s disease. 
2464 cases. 1220 deaths. 
 
Prescribed AChEI Hazard ratio (95% CI) 
Crude 0.57 (0.51-0.64)* 
Adjusted for age and gender 0.65 (0.58-0.73)* 
Adjusted for all demographics 0.65 (0.58-0.74)* 
Adjusted for demographics and cognitive scores 0.73 (0.64-0.83)* 
Adjusted for demographics, cognitive scores, and psychotropic 
prescription 
0.73 (0.64-0.83)* 
Adjusted for demographics, cognitive and HoNOS65+ scores 0.76 (0.67-0.87)* 
Adjusted for demographics, cognitive scores, and hospital 
episode statistics 
0.75 (0.66-0.85)* 
Fully adjusted (all of above) 0.77 (0.67-0.88)* 
Adjusted using propensity score as a covariate 0.78 (0.68-0.89)* 
Fully adjusted including those at risk of being treated with AChEI 0.77 (0.67-0.87)* 
 
* p<0.05 
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Supplementary Figure 
 
 
Figure 1: Kaplan-Meier curves displaying the survival status of Alzheimer’s disease 
patients comparing those who received AChEIs and those who did not (n=2464); 
95% confidence interval 
 
 
 
 
 
 
 
